[et_pb_section fb_built=”1″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
In the current issue of the specialist journal FRAUENARZT (9\/2025, p. 628-634)<\/strong>, Prof. Peter Hillemanns<\/strong> (Hannover Medical School), Prof. Julia Gallwas<\/strong> (University Medical Center G\u00f6ttingen) and Prof. Martin Widschwendter<\/strong> (EUTOPS, University of Innsbruck\/LKH Hall) address the question of how new biomarkers can improve the diagnosis of endometrial cancer. The article focuses in particular on DNA methylation assays<\/strong> – an approach that Sola Diagnostics GmbH is also consistently pursuing. <\/p>\n DNA methylation tests<\/strong> are based on the detection of epigenetic changes that play a central role in tumor development and progression. In contrast to purely morphological methods, these molecular markers can provide indications of malignant changes at a very early stage. The FRAUENARZT article emphasizes that several test procedures – including WID\u00ae-easy, CISENDO\u00ae and MPap\u00ae<\/strong> – have shown high diagnostic accuracy in studies. The advantage becomes particularly clear when compared with transvaginal ultrasound: while TVS has a high sensitivity but low specificity, methylation assays achieve values that combine both dimensions. For example, the authors report a sensitivity of 91 % and a specificity of 97 %<\/strong> for the WID\u00ae-easy test.<\/strong> <\/p>\n In addition to pure performance, another advantage of these tests is the potential reduction in unnecessary invasive procedures<\/strong>. By improving the differentiation between benign and malignant changes, patients could be diagnosed in a more targeted and gentle manner. In this context, the article outlines a possible future diagnostic pathway in which DNA methylation tests are systematically integrated. <\/p>\n For Sola Diagnostics GmbH, this publication confirms the path we have taken: our work is based precisely on this principle – the integration of DNA methylation methods into clinical practice<\/strong> in order to make diagnostics for endometrial cancer more precise, gentle and patient-oriented<\/strong>. The article in FRAUENARZT makes it clear that these technologies are now not only being discussed in research, but have also arrived in clinical practice. <\/p>\n We see this as a clear confirmation of our mission: to consistently develop innovative molecular diagnostics in such a way that they become an integral part of diagnostic standards in the future – in the interests of patients and treating physicians alike.<\/strong><\/p>\n